A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction-Reference-Cited by-同舟云学术

A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction

Published:2017-07-05 Issue:10 Volume:19 Page:1321-1332
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Tita Cristina¹,Gilbert Edward M.²,Van Bakel Adrian B.³,Grzybowski Jacek⁴,Haas Garrie J.⁵,Jarrah Mohammad⁶,Dunlap Stephanie H.⁷,Gottlieb Stephen S.⁸,Klapholz Marc⁹,Patel Parag C.¹⁰,Pfister Roman¹¹,Seidler Tim¹²,Shah Keyur B.¹³,Zieliński Tomasz¹⁴,Venuti Robert P.¹⁵,Cowart Douglas¹⁵,Foo Shi Yin¹⁵,Vishnevsky Alexander¹⁶,Mitrovic Veselin¹⁷

Affiliation:

1. Division of Cardiovascular Medicine, Department of Medicine; Henry Ford Hospital; Detroit MI USA

2. Division of Cardiology, Faculty of Medicine; University of Utah; Salt Lake City UT USA

3. Division of Cardiology, Department of Medicine; Medical University of South Carolina; Charleston SC USA

4. Department of Cardiomyopathy; Institute of Cardiology; Warsaw Poland

5. Division of Cardiology and Vascular Medicine, Faculty of Medicine; Ohio State University; Columbus OH USA

6. Department of Cardiology; King Abdullah University Hospital; Irbid Jordan

7. Division of Cardiology, Faculty of Medicine; University of Cincinnati; Cincinnati OH USA

8. Division of Cardiovascular Medicine; University of Maryland School of Medicine; Baltimore MD USA

9. Division of Cardiology; Rutgers New Jersey Medical School; Newark NJ USA

10. Department of Transplant; Mayo Clinic; Jacksonville FL USA

11. Department III of Internal Medicine, Heart Centre; University Hospital of Cologne; Cologne Germany

12. Division of Cardiology and Pulmonology; Medical University of Göttingen; Göttingen Germany

13. Department of Cardiology, Faculty of Medicine; Virginia Commonwealth University; Richmond VA USA

14. Department of Heart Failure and Transplantology; Institute of Cardiology; Warsaw Poland

15. formerly of Cardioxyl Pharmaceuticals, Inc.; Chapel Hill NC USA

16. Intensive Care Unit, Cardiology Department; Pokrovskaya City Hospital; St Petersburg Russia

17. Department of Cardiology; Kerckhoff-Klinik; Bad Nauheim Germany

Funder

Cardioxyl Pharmaceuticals

Bristol-Myers Squibb

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ejhf.897/fullpdf

Reference33 articles.

1. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines;Yancy;J Am Coll Cardiol,2013

2. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC;Ponikowski;Eur J Heart Fail,2016

3. Acute decompensated heart failure: treatments and challenges;Greenberg;Circ J,2012

4. The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO;Paolocci;Pharmacol Ther,2007

5. Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling;Tocchetti;Circ Res,2007

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Antioxidants in the Therapy of Cardiovascular Diseases—A Literature Review;Nutrients;2024-08-06

2. An Unexpected Degradation Pathway of N-Hydroxy-5-Methylfuran-2-Sulfonamide (BMS-986231), a pH Sensitive Prodrug of HNO, in a Prototype Formulation Solution;Journal of Pharmaceutical Sciences;2024-08

3. Decoding the enigmatic last gasotransmitter. The intriguing journey of HNO: From hidden origins to clues on reactivity and detection;Redox Biochemistry and Chemistry;2024-06

4. Can non-invasive cardiac hemodynamics and fluid content system (NICaS) parameters predict Acute Heart Failure outcomes in Caucasian and Asian patients in the emergency department?;Advances in Medical Sciences;2024-03

5. Targeting Key Inflammatory Mechanisms Underlying Heart Failure: A Comprehensive Review;International Journal of Molecular Sciences;2023-12-29